Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Disgnostic Substances)
Latest available SEC filing: 4 ·
Latest disclosures
-
Douglas Earl Martin: Form 4
Insider disclosure · Filed · Report period 21 Aug 2026
-
Form 4
SEC filing · Filed
-
Form SCHEDULE 13G/A
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- ALLO · 019770106 - Common Stock, par value $0.001 per share
Company details and SEC sources
CIK 0001737287 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- ALLO on Nasdaq
- SEC industry group
- Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
- Business address
- 210 East Grand Avenue, South San Francisco, CA, 94080
- Fiscal year end
- 31 December
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields